BRPI0308706B8 - hidrato de darifenacina, e processo para sua preparação - Google Patents

hidrato de darifenacina, e processo para sua preparação

Info

Publication number
BRPI0308706B8
BRPI0308706B8 BRPI0308706A BR0308706A BRPI0308706B8 BR PI0308706 B8 BRPI0308706 B8 BR PI0308706B8 BR PI0308706 A BRPI0308706 A BR PI0308706A BR 0308706 A BR0308706 A BR 0308706A BR PI0308706 B8 BRPI0308706 B8 BR PI0308706B8
Authority
BR
Brazil
Prior art keywords
bladder
urinary
hydrate
treatment
receptor antagonist
Prior art date
Application number
BRPI0308706A
Other languages
English (en)
Other versions
BR0308706A (pt
BRPI0308706B1 (pt
Inventor
O'oconnor Garry
George Matthews John
James Dunn Peter
Jack Newbury Trevor
Original Assignee
Aspen Global Incorporated
Novartis Int Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0308706(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aspen Global Incorporated, Novartis Int Pharmaceutical Ltd filed Critical Aspen Global Incorporated
Publication of BR0308706A publication Critical patent/BR0308706A/pt
Publication of BRPI0308706B1 publication Critical patent/BRPI0308706B1/pt
Publication of BRPI0308706B8 publication Critical patent/BRPI0308706B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"hidrato estável de um antagonista de receptor muscarínico". a presente invenção refere-se a um hidrato sólido estável de um antagonista de receptor muscarínico que é útil no tratamento de síndrome de intestino irritável, doença diverticular, acalasia esofageal, doença de vias aéreas obstrutivas crônica, bexiga super ativa incluindo sintomas de incontinência, urgência e freqüência, incontinência urinária, urgência urinária neurogênica ou polaquiúria, tratamento de distúrbio funcional de bexiga, vazamento urinário, micção difícil ou dolorosa causada por bexiga neurogênica, bexiga hipertônica ou espástica, síndrome de bexiga disfuncional, distúrbios gastrointestinais incluindo hiperatividade gastrointestinal, e efeito relaxante sobre células de músculo liso.
BRPI0308706A 2002-03-26 2003-03-17 hidrato de darifenacina, e processo para sua preparação BRPI0308706B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0207104.1A GB0207104D0 (en) 2002-03-26 2002-03-26 Stable hydrate of a muscarinic receptor antagonist
GB0207104.1 2002-03-26
PCT/IB2003/001043 WO2003080599A1 (en) 2002-03-26 2003-03-17 Stable hydrate of a muscarinic receptor antagonist

Publications (3)

Publication Number Publication Date
BR0308706A BR0308706A (pt) 2005-01-04
BRPI0308706B1 BRPI0308706B1 (pt) 2018-07-10
BRPI0308706B8 true BRPI0308706B8 (pt) 2021-05-25

Family

ID=9933731

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0308706A BRPI0308706B8 (pt) 2002-03-26 2003-03-17 hidrato de darifenacina, e processo para sua preparação
BR122018000397A BR122018000397B8 (pt) 2002-03-26 2003-03-17 solvato de darifenacina, e processo para sua preparação

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122018000397A BR122018000397B8 (pt) 2002-03-26 2003-03-17 solvato de darifenacina, e processo para sua preparação

Country Status (23)

Country Link
US (3) US6930188B2 (pt)
EP (2) EP1490357B1 (pt)
JP (2) JP2005524678A (pt)
KR (4) KR20120098888A (pt)
CN (1) CN100345840C (pt)
AR (1) AR042608A1 (pt)
AT (1) ATE495169T1 (pt)
AU (1) AU2003209921A1 (pt)
BR (2) BRPI0308706B8 (pt)
CA (1) CA2480287C (pt)
CY (2) CY1111200T1 (pt)
DE (1) DE60335711D1 (pt)
DK (2) DK2336124T3 (pt)
ES (2) ES2358644T3 (pt)
GB (1) GB0207104D0 (pt)
HK (2) HK1080847A1 (pt)
PA (1) PA8569701A1 (pt)
PT (2) PT1490357E (pt)
SI (2) SI2336124T1 (pt)
SV (1) SV2003001515A (pt)
TW (1) TW200306816A (pt)
UY (1) UY27735A1 (pt)
WO (1) WO2003080599A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
AU2006239941A1 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
US20070197630A1 (en) * 2005-12-27 2007-08-23 Valeriano Merli Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
EP2109601A2 (en) * 2007-01-05 2009-10-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
RU2452728C2 (ru) * 2007-02-23 2012-06-10 Тереванс, Инк. Четвертичные аммониевые дифенилметилсоединения, применимые в качестве антагонистов мускариновых рецепторов
WO2008144602A1 (en) * 2007-05-18 2008-11-27 Auspex Pharmaceuticals, Inc. Deuterated zamifenacin derivatives
WO2009007853A2 (en) * 2007-06-08 2009-01-15 Actavis Group Ptc Ehf Novel polymorphs of darifenacin free base and its hydrobromide salt
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
AR068322A1 (es) * 2007-07-13 2009-11-11 Medichem Sa Forma amorfa de hidrobromuro de darifenacina y procedimientos para su preparacion
CZ200845A3 (cs) 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
EP2261205A4 (en) 2008-04-02 2012-06-06 Kaneka Corp PROCESS FOR PRODUCING (S) -3- (1-CYANO-1,1-DIPHENYLMETHYL) -PYRROLIDINE
WO2010032225A2 (en) * 2008-09-22 2010-03-25 Watson Pharma Private Limited Process for preparation of darifenacin and intermediates used in the process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
AU2016371762A1 (en) * 2015-12-14 2018-06-21 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
DK3497075T3 (da) * 2016-08-12 2020-08-31 Bayer Cropscience Ag Fremgangsmåde til fremstilling af substituerede styren-derivater

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
AU4421697A (en) * 1996-09-19 1998-04-14 American Home Products Corporation Method of treating urinary incontinence
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
US7696357B2 (en) 2010-04-13
US20050245597A1 (en) 2005-11-03
CY1113433T1 (el) 2016-06-22
BR0308706A (pt) 2005-01-04
CN1642945A (zh) 2005-07-20
HK1080847A1 (en) 2006-05-04
ES2394067T3 (es) 2013-01-16
CY1111200T1 (el) 2015-06-11
ES2358644T3 (es) 2011-05-12
SV2003001515A (es) 2003-12-15
ATE495169T1 (de) 2011-01-15
AU2003209921A1 (en) 2003-10-08
TW200306816A (en) 2003-12-01
UY27735A1 (es) 2003-10-31
CA2480287A1 (en) 2003-10-02
HK1156626A1 (en) 2012-06-15
KR20100101182A (ko) 2010-09-16
EP1490357A1 (en) 2004-12-29
US20030191176A1 (en) 2003-10-09
DE60335711D1 (de) 2011-02-24
AR042608A1 (es) 2005-06-29
KR101212908B1 (ko) 2012-12-14
SI2336124T1 (sl) 2012-12-31
JP2005524678A (ja) 2005-08-18
SI1490357T1 (sl) 2011-05-31
PA8569701A1 (es) 2003-12-10
DK2336124T3 (da) 2012-12-17
BR122018000397B8 (pt) 2021-07-27
JP2010195828A (ja) 2010-09-09
KR20040093477A (ko) 2004-11-05
KR101026283B1 (ko) 2011-03-31
US20080167367A1 (en) 2008-07-10
EP2336124B1 (en) 2012-08-29
EP2336124A1 (en) 2011-06-22
KR20110130539A (ko) 2011-12-05
CN100345840C (zh) 2007-10-31
WO2003080599A1 (en) 2003-10-02
US6930188B2 (en) 2005-08-16
GB0207104D0 (en) 2002-05-08
BRPI0308706B1 (pt) 2018-07-10
PT2336124E (pt) 2012-12-12
KR20120098888A (ko) 2012-09-05
CA2480287C (en) 2011-05-31
PT1490357E (pt) 2011-03-01
DK1490357T3 (da) 2011-04-04
EP1490357B1 (en) 2011-01-12
BR122018000397B1 (pt) 2019-07-02

Similar Documents

Publication Publication Date Title
BRPI0308706B8 (pt) hidrato de darifenacina, e processo para sua preparação
Bonnet et al. Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial
BRPI0509298A (pt) composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
US20060173052A1 (en) Use of the non-opiate analgesic drug flupirtine of the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowl syndrome
MA31004B1 (fr) Dispersion solide d'un antagoniste de la neurokinine
NO20064050L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av sovnforstyrrelser i den deprimerte pasient
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
BR0104830A (pt) Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
MA30556B1 (fr) COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE.
NO338713B1 (no) Anvendelse av (R)-(halobenzyloksy)benzylamino-propanamider som natrium- og/eller kalsiumkanalmodulatorer
EA200801488A1 (ru) Замещенные фенетиламины, обладающие серотонинергической и/или норэпинефринергической активностью
TW200914022A (en) Synergistic combinations
EA200970451A1 (ru) Новые производные триазиндионов в качестве модуляторов рецептора гамк
BRPI0511305A (pt) método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1
US11458142B2 (en) Compositions and methods for ameliorating pain
Wanajo et al. The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics
RU2005125047A (ru) Соединения карбоновых кислот
Wanajo et al. Ureteral selectivity of intravenous β-adrenoceptor agonists in pig model of acute ureteral obstruction: comparison of KUL-7211, a selective β2/β3 agonist, with isoproterenol, terbutaline, and CL-316243
WO2008037045A3 (en) Composition containing a mixture of antidepressants for treating premature ejaculation.
WO2002083074A3 (en) Methods for the treatment of hepatic disorders
Thaminy et al. Is chlormethiazole neuroprotective in experimental global cerebral ischemia? A microdialysis and behavioral study
JP5564263B2 (ja) ムスカリンｍ１、ｍ２およびｍ３受容体の選択的阻害を有する薬剤の製造のための１０−［（３ｒ）−１−アザビシクロ［２．２．２］オクト−３−イルメチル］−１０ｈ−フェノチアジンの使用
DOP2003000615A (es) Hidrato estable de un antagonista de receptores muscarinicos
AR033830A1 (es) Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ASPEN GLOBAL INCORPORATED (MR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: ASPEN GLOBAL INCORPORATED (MR)

B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: ZODIAC PRODUTOS FARMACEUTICOS S.A. - PETICAO NO870190002945 DE 10/01/2019.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 17/03/2023